Vertex Pharmaceuticals Stock Is Soaring: Here's Why It's Still Not Too Late to Buy
Just last week, I wrote why you'd be smart to buy Vertex Pharmaceuticals (NASDAQ: VRTX) stock. At that time, Vertex was up around 70% for the year. My argument then was that the stock was still undervalued even with a forward earnings multiple of 41 because of its growth prospects, particularly with its three-drug combination treatments for cystic fibrosis (CF).
Vertex announced results from phase 1 and phase 2 studies of three different triple-combination CF therapies on Tuesday. To call those results positive would be an understatement. The biotech's share price soared more than 20% on the news of just how successful the triple-combo regimens were.
With Vertex stock at all-time highs, is it too late to buy shares of this hot biotech? Here's why I still think the answer to that question is a resounding "no."
Source: Fool.com
Vertex Pharmaceuticals Inc. Aktie
Die Vertex Pharmaceuticals Inc. Aktie zieht viel Aufmerksamkeit auf sich: Viel mehr Buy- als Sell-Einschätzungen.
Ein Kursziel von 440 € für Vertex Pharmaceuticals Inc. zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 422.25 €.
